Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ARVNNASDAQ:MTSRNASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$37.38+4.2%$25.85$16.50▼$37.95$3.26BN/A12,996 shs25,208 shsARVNArvinas$7.44-0.4%$7.46$5.90▼$34.11$543.06M2.21.44 million shs2.15 million shsMTSRMetsera$29.60+6.8%$25.70$12.30▼$37.99$3.11BN/A977,849 shs2.03 million shsNAMSNewAmsterdam Pharma$17.96-1.3%$18.51$14.06▼$27.29$2.02B-0.03699,446 shs1.01 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+18.63%+46.24%+99.89%+3,737,999,900.00%ARVNArvinas0.00%+0.68%+14.99%-14.97%-70.02%MTSRMetsera0.00%+0.75%+5.53%+5.64%+2,959,999,900.00%NAMSNewAmsterdam Pharma0.00%-11.13%-1.75%-24.76%+4.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AARVNArvinas3.7462 of 5 stars4.34.00.00.02.31.71.3MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma2.9925 of 5 stars3.52.00.00.02.65.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AARVNArvinas 2.55Moderate Buy$20.29172.71% UpsideMTSRMetsera 3.00Buy$55.0085.81% UpsideNAMSNewAmsterdam Pharma 3.00Buy$42.89138.80% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, AAPG, NAMS, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/12/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.006/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M24.24N/AN/A$0.48 per share77.88ARVNArvinas$263.40M2.06N/AN/A$8.17 per share0.91MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/ANAMSNewAmsterdam Pharma$45.56M44.26N/AN/A$8.20 per share2.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)Latest ARVN, AAPG, NAMS, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26ARVNArvinasN/A4.584.58MTSRMetseraN/A6.556.55NAMSNewAmsterdam PharmaN/A19.9819.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas95.19%MTSRMetseraN/ANAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas4.73%MTSRMetseraN/ANAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/AARVNArvinas42072.99 million69.54 millionOptionableMTSRMetsera81105.06 millionN/AN/ANAMSNewAmsterdam Pharma4112.27 million88.87 millionOptionableARVN, AAPG, NAMS, and MTSR HeadlinesRecent News About These CompaniesNewAmsterdam Pharma (NASDAQ:NAMS) Lowered to "Sell" Rating by Wall Street ZenJune 22 at 2:15 AM | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Downgraded by Wall Street Zen to "Sell"June 21 at 2:54 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - Time to Buy?June 20 at 11:55 AM | marketbeat.comJames N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) StockJune 19 at 7:42 AM | insidertrades.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of "Buy" by AnalystsJune 19 at 4:43 AM | marketbeat.comCiti initiates NewAmsterdam Pharma stock with buy rating on cholesterol drugJune 18, 2025 | investing.comJames N. Topper Purchases 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) StockJune 18, 2025 | marketbeat.comInsider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 100,000 Shares of StockJune 18, 2025 | marketbeat.comCitigroup Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)June 18, 2025 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Analysts at CitigroupJune 17, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Needham & Company LLCJune 15, 2025 | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) versus NewAmsterdam Pharma (NASDAQ:NAMS) Critical ReviewJune 14, 2025 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Handelsbanken Fonder ABJune 13, 2025 | marketbeat.com5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...June 12, 2025 | benzinga.comStrong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s OpportunitiesJune 12, 2025 | tipranks.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at Needham & Company LLCJune 12, 2025 | marketbeat.comStifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationJune 11, 2025 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at StifelJune 11, 2025 | insidermonkey.comNewAmsterdam Pharma Rings the Closing BellJune 11, 2025 | nasdaq.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.4% - Should You Sell?June 11, 2025 | marketbeat.comNewAmsterdam Pharma Schedules R&D Day for June 2025June 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, AAPG, NAMS, and MTSR Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$37.38 +1.50 (+4.18%) As of 06/20/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arvinas NASDAQ:ARVN$7.44 -0.03 (-0.40%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.40 -0.04 (-0.59%) As of 06/20/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Metsera NASDAQ:MTSR$29.60 +1.89 (+6.82%) As of 06/20/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.NewAmsterdam Pharma NASDAQ:NAMS$17.96 -0.24 (-1.32%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$18.15 +0.19 (+1.06%) As of 06/20/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
